Showing results (251-260 of 321) with videos related to

Sort By:
Pageof 33
International Journal of Environmental Research and Public Health|January 31, 2014
Cancer cluster investigations: review of the past and proposals for the futureMichael Goodman, Judy S LaKind, Jerald A Fagliano, et al.
European Urology Oncology|October 14, 2023
Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE)Laurence Klotz, Joseph Chin, Peter C Black, et al.
European Journal of Human Genetics : EJHG|June 1, 2019
Attitudes of Australian health professionals towards rapid genomic testing in neonatal and paediatric intensive careZornitza Stark, Amy Nisselle, Belinda McClaren, et al.
Nephrology (Carlton, Vic.)|August 4, 2015
Identifying and integrating consumer perspectives in clinical practice guidelines on autosomal-dominant polycystic kidney diseaseAllison Tong, David J Tunnicliffe, Pamela Lopez-Vargas, et al.
BMJ Open|August 7, 2019
Comprehensive evaluation of a prospective Australian patient cohort with suspected genetic kidney disease undergoing clinical genomic testing: a study protocolKushani Jayasinghe, Zornitza Stark, Chirag Patel, et al.
The Journal of Vascular Access|March 14, 2018
Prevalence of chronic kidney disease among patients undergoing transradial percutaneous coronary interventionsMohammad A Hossain, Amy Quinlan, Jennifer Heck-Kanellidis, et al.
Clinical Lung Cancer|March 24, 2020
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working GroupPatrick M Forde, Phil Bonomi, Alice Shaw, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Comparative effectiveness of standard vs. AI-assisted PET/CT reading workflow for pre-treatment lymphoma staging: a multi-institutional reader study evaluationRussell Frood, Julien M Y Willaime, Brad Miles, et al.
Journal of Clinical Pharmacology|August 12, 2017
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic AnalysisNeeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, et al.
International Journal of Cancer|March 22, 2006
Cathepsin S expression: An independent prognostic factor in glioblastoma tumours--A pilot studyThomas Flannery, Stephen McQuaid, Caroline McGoohan, et al.
Pageof 33